

Diwali

Picks - 2022



Diwali Picks 2022

Script Name	CMP as on 14-Oct-22	Target Price	Upside Potential	Market Cap. (₹Bn.)	PE/PB (FY24E)	Rationale/Description
Anupam Rasayan Ltd.	725	940	30%	73	26.4	The company is targeting launch of seven new products in FY23 and has pipeline of 90 products at various levels of R&D and pilot scale. With the completion of major capacity expansion exercise the company is set to ramp up its production in near term. We believe ANURAS with strong pipeline of products, ramp up of new capacities and competency in key complex chemistries could continue to grow at high rates.
Max Healthcare Institute Ltd.	427	504	18%	415	31.4	Maxhealth continues to record healthy performance with considerable improvement in ARPOB, maintaining its industry leading margins and strong balance sheet. The company reported the highest ever EBITDA per bed in Q1FY23, which is expected to improve further with the favourable payor mix change in the coming years.
Tarsons Products Ltd	802	974	21%	43	33	A leading labware equipment player providing high-quality and cost-effective plastic labware products across Academia/Research and Pharmaceutical industries with growing market share and presence in the high margin exports market (29% of FY22 revenues). Surge in outsourcing by pharmaceutical companies and increasing awareness and testing requirements in diagnostics space can drive further growth.
State Bank of India	527	650	23%	4,705	1.5	SBI is witnessing strong advance growth with increase in retail consumption, corporate demand and agriculture improvement due to monsoon and Government CapEx. SBI has a diversified loan book, one of the best liability franchises with CASA mix of 45% and improving balance sheet.
Mrs.Bectors Food Specialities Ltd.	375	455	21%	22	31	With Branded biscuits, Breads & Buns & Chain QSR Market expected to grow at a CAGR of 12%/11%/29% we expect huge runway of growth ahead for Mrs.Bectors Food owing to rising distribution reach enhancing product portfolio and deepening relationships with leading QSR players to capture further growth.
Linde India Limited	3,150	3,800	21%	268	52	Linde India is all set to register good growth driven by increasing manufacturing activities from downstream industry like steel, cement etc, new capacities coming on-stream and Synergies benefit from JV with Praxair India. The Company also has debt free Balance sheet and good financial profile.

Anupam Rasayan India Limited (ANURAS)

CMP: ₹725
Target: ₹940

ANAND RATHI
INVESTMENT SERVICES


Rationale:

- Anupam Rasayan India Limited (ANURAS) is a established Custom Synthesis company with 38 years of track record. The company Specializes in multi-step synthesis undertaking complex chemical reactions to produce key specialty chemicals with focus on developing innovative manufacturing processes. It primarily operates in two verticals, namely Life Science related Specialty Chemicals and Other Specialty Chemicals. The company has already manufactures 48 Complex products as of Q1FY23.
- The company has a strong technical capabilities in complex chemistries supported by an R&D team of 85 professionals. It has 27,200 MT of manufacturing capacity, spread over 6 manufacturing facilities and a strong supply chain with backward integrated facilities. The company caters to globally relevant chemical & agrochemical companies, including 26 MNCs and cumulative 70 clients.
- The company's key competency areas in chemistry includes Chlorination, Etherification, Diazotization & hydrolysis, Acylation, Hydrogenation, Fluorination, Alkylation, Nitration, Amination and Esterification with process technologies like Flow chemistry and Photo chemistry.
- During the latest quarterly results the company has reported a healthy growth of 38.9% in its consolidated revenues at ₹1,031.7 million in Q1-FY23. The operating profit for the company grew by 45% at ₹254.9 millions while profit after tax grew by 70.7% at ₹162 millions.
- The company has shown consistent improvement in new product addition over last few years and its product portfolio has increased to 48 in Q1FY23 from 25 products in FY18, a CAGR of around 17.7%. The management is targeting launch of seven new products in FY23 and has pipeline of 90 products at various levels of R&D and pilot scale.
- Also, the company has recently acquired 26% stake in Tanfac Industries which would aide the company in launch of fluorine based products and polymer intermediates like fluoro elastomers and fluoro electrolytes which are key ingredients in semi-conductors etc.
- With the completion of major capacity expansion exercise the company is set to ramp up its production in near term. We believe ANURAS with strong pipeline of products, ramp up of new capacities and competency in key complex chemistries could continue to grow at high rates in medium term. We initiate our coverage on the company with **BUY** rating and a target price of **₹940 per share.**

52 Week Low / High	547 / 1107
Avg. Daily Volume (3M)	114
No. of Shares O/S (Mn.) / Mkt. Cap (₹Mn.)	100.3 / 72699
Shareholding (Promoters/Institutional/Others)	65.2/ 9.4/ 25.5

(In ₹ mn)	FY-21	FY-22	FY-23E	FY-24E
Total Income	8,375	10,811	14,186	17,932
EBITDA	2,202	3,121	3,800	4,806
EBITDA Margin	26.3%	28.9%	26.8%	26.8%
PAT	703	1,515	1,959	2,757
PAT Margin	8.4%	14.0%	13.8%	15.4%
EPS (₹)	7.01	15.11	19.54	27.49
Debt/Equity	0.25	0.46	0.26	0.25
P/B	4.62	4.22	3.79	3.31
RoE	6.6%	9.2%	10.2%	12.6%
P/E	103.4	48.0	37.1	26.4

Source: Company, Anand Rathi Research, Bloomberg. Note: Prices are as on 14-Oct-22



Max Healthcare Institute Limited (MAXHEALTH)

CMP: ₹ 427
Target: ₹ 504

ANAND RATHI
INVESTMENT SERVICES

Rationale:


- Max Healthcare Institute Limited (Max Healthcare) is one of the largest integrated healthcare providers in the country. They own, operate and provide medical services to facilities in Delhi NCR, Mumbai, Punjab, Uttar Pradesh and Uttarakhand. Max Lab supplements their commitment towards patient care by providing accurate testing and diagnostics.
- Besides the core hospital business (96% of total revenues), it also operates two strategic business units (SBUs) – Max Lab (non-captive pathology diagnostic services) and Max@Home (health and wellness services at home). Through Max Lab, the company provides diagnostic, pathology, radiology, radiation oncology and clinical services, through fee and/or revenue sharing agreements, in select specialties and departments to its Partner Healthcare Facilities and Managed Healthcare Facilities. Presently, Max Lab also has operations in the NCR region, Chandigarh, Panchkula, Mohali and key cities in Punjab and Uttarakhand.
- The Max health has also executed four transactions with potential to add 2,200 beds in the upcoming year. Acquisition of exclusive rights to aid development and provide medical services to an upcoming 500 bed hospital in Saket along with acquisition of two land parcels in Gurugram admeasuring 11 acres with capacity to add 1,000 beds. The company is expanding through Asset light model where a 300 bed under construction hospital in Dwarka, Delhi.
- The key highlights for the 1QFY23 one performance were, the average occupancy for the quarter recovered to 74% from 68% in quarter four FY22, which was largely impacted due to the Omicron COVID wave in the first half of Q4FY22. The bed share of institutional patients, relatively a lower ARPOB channel, has been brought down to 30% from 33% in Q4. This has added to growth in ARPOB, as well as EBITDA per bed. This is in line with management guidance and objectives. The ARPOB for this quarter rose to Rs. 66,000 implying a growth of 28% YoY and 4% QoQ.
- The company further growth strategy is to increasing medical value travel in old and new geographies, improving pay or mix, inorganic acquisition in hospital/ diagnostic space (in North and West). Overall capex outlay for next 5-7 years at ₹ 40 billion for doubling capacity to be spent largely through internal accruals. We believe the company to continue to grow with strong balance sheet, we initiate our coverage on MAXHEALTH with a **BUY** rating and a target price of **₹ 504 per share**.

52 Week Low / High	458 / 306
Avg. Daily Volume (3M)	1780.34
No. of Shares O/S (Mn.) / Mkt. Cap (₹Mn.)	969.6 / 414,630
Shareholding (Promoters/Institutional/Others)	50.6% / 42.8% / 6.6%

(In ₹ mn)	FY-21	FY-22	FY-23E	FY-24E
Total Income	36,007	51,709	57,397	64,859
EBITDA	6,085	13,431	15,268	17,341
EBITDA Margin	16.9%	26.0%	26.6%	26.7%
PAT	(940)	8,367	10,045	11,419
PAT Margin	(-3.0%)	16.2%	17.5%	17.6%
EPS (₹)	(0.95)	8.6	10.4	11.7
Debt/Equity	0.2	0.1	0.1	0.1
P/B	6.4	5.8	4.8	4.2
RoE	3.2%	14.2%	13.4%	13.6%
P/E	193.7	49.6	35.7	31.4

Source: Company, Anand Rathi Research, Bloomberg. Note: Prices are as on 14-Oct-22

Price Performance (Oct'21=100)



Tarsons Products Limited (TARSONS)

CMP: ₹802
Target: ₹974

ANAND RATHI
INVESTMENT SERVICES

Rationale:


- Tarsons Products Ltd (Tarsons) is one of the leading plastic labware companies in India with over ~25% share in the plastic labware equipment market. The company provides high-quality and cost-effective plastic labware. It has a sales team of 50-member sales team spread across the country focusing on enhancing brand awareness for Tarsons' products, besides facilitating distributors. Of the total distributors, 75–80% have been associated with Tarsons for more than two decades. This indicates that the company has a strong and well-diversified distribution network across India.
- The labware manufacturer caters to variety of end-user industries namely Academic Institutes & Research Organization, Pharmaceutical industry, Contract Research Organization, Diagnostics industry and Exports market. The Academia/Research and Pharmaceutical combined contributed to majority of the end-user industry up to over ~60% of the market. Surge in outsourcing by pharmaceutical companies and increasing awareness and testing requirements is in the diagnostics space is expected to register accelerated growth in the end-user industries.
- Tarsons runs five manufacturing plants spanning 21,000 sq.m. After building the new manufacturing facility in Panchla and Amta, West Bengal, the company is increasing its manufacturing capacity for both current and new products bringing the manufacturing land area to over 42,000 square metres (2x of current 21,256 sq.m). It has envisaged capex of Rs.5,000 Mn out of which Rs.2,500 Mn is already incurred and execution of existing facilities is on track. Subsequently, Tarsons would be able to cater to strong demand from both export and domestic markets and foray into the PCR and cell culture space; this would raise the target addressable market to ~Rs.12 Bn.
- Tarsons Products reported a robust CAGR growth of 19%/29%/37% in its Revenue/EBITDA/PAT over FY19-FY22 respectively followed by industry leading EBITDA/PAT margin which stood at a whopping 51%/31% respectively in FY22. This was mainly led by strong growth in export markets and new product launches.
- We expect Revenue/EBITDA/PAT to grow at a CAGR of 18%/16%/14% respectively by FY24 with margins relatively being stable. We recommend **BUY** rating on TARSONS with a target price of **₹974 per share**.

52 Week Low / High	538.70 / 924.90
Avg. Daily Volume (3M)	215
No. of Shares O/S (Mn.) / Mkt. Cap (₹Mn.)	53.21 / 42,690
Shareholding (Promoters/Institutional/Others)	47.3% / 9.3% / 43.4%

(In ₹ mn)	FY-21	FY-22	FY-23E	FY-24E
Total Income	2,289	3,008	3,549	4,153
EBITDA	1,034	1,527	1,739	2,035
EBITDA Margin	45.19%	50.77%	49.00%	49.00%
PAT	689	1,007	1,080	1,295
PAT Margin	30.09%	33.47%	30.44%	31.19%
EPS (₹)	12.9	18.9	20.3	24.3
Debt/Equity	0.1	0	0	0
P/B	17.5	8.7	7.2	5.9
RoE	28.19%	20.55%	18.07%	17.81%
P/E	62.1	42.5	39.6	33.0

Source: Company, Anand Rathi Research, Bloomberg. Note: Prices are as on 14-Oct-22

Price Performance (Nov'21=100)



Rationale:


- State Bank of India provides a wide range of products and services to individuals, commercial enterprises, large corporates, public bodies, and institutional customers through its various branches and outlets, joint ventures, subsidiaries, and associate companies.
- SBI is witnessing strong advance growth with increase in retail consumption, corporate demand and agriculture improvement due to monsoon and Government CapEx. Tightened system liquidity could be another factor for credit growth, as corporates turn towards banks for satisfying their working capital requirements. Although there could be challenges due to global macro factors. SBI has given a credit growth guidance of ~14-15% on the back of healthy demand pipeline to aid business growth and overall performance
- SBI has a diversified loan book with Retail loans contributing 42%, Corporate loans 36%, SME loans 13% & Agri loans contributing 9% of the total loan book in Q1-FY23. During FY-2022, SBI's advances grew by 11% to ₹28.18 lakh crores, compared to growth of 4.8% in FY-2021 & in Q1-FY23 advances grew by 15% YoY.
- The bank has one of the best liability franchises with CASA mix of 45%. This puts SBI in a better position to manage pressure on yields and support margin to a large extent in a rising interest rate scenario. SBI aspires to increase market share in current account to increase CASA ratio.
- The GNPA stood at 3.91%, a decline of 141 bps YoY, and NNPA at 1.0% a decline of 77 bps YoY. The slippages for Q1-FY23 stood at ₹97.4 Bn declined by 37.8% YoY, with a slippage ratio of 1.4% in Q1-FY23 as against 2.5% in Q4-FY22. The recoveries for Q1-FY23 stood at ₹52,080 Mn. The PCR improved sharply by 719 bps YoY at 75.1%. We expect the slippages to remain moderate with healthy recoveries.
- We are positive on SBI given strong traction in credit growth and high CASA mix to sustain its margins at sustainable levels. On the asset quality front, improvement of slippages and recoveries are encouraging. In addition to SBI's strong banking business, robust performance was reported by its subsidiaries SBILIFE, SBICARD, SBI MF and SBI Cap. We initiate a **BUY** on SBI with a target price of ₹650 per share.

52 Week Low / High	425.00 / 578.65
Avg. Daily Volume (3M)	13478
No. of Shares O/S (Mn.) / Mkt. Cap (₹Mn.)	8924.61 / 4,705,055
Shareholding (Promoters/Institutional/Others)	57.57% / 34.86% / 7.57%

(In ₹ mn)	FY-21	FY-22	FY-23E	FY-24E
Net Interest Income	1,107,100	1,207,076	1,367,532	1,518,952
Operating Profit	715,542	678,740	764,372	895,814
PAT	204,105	259,715	386,710	463,330
EPS (₹)	22.9	29.1	43.3	51.9
P/E	23.01	18.11	12.17	10.15
P/B	2.04	1.66	1.66	1.46

Source: Company, Anand Rathie Research, Bloomberg. Note: Prices are as on 14-Oct-22

Price Performance (Oct'21=100)



Mrs.Bectors Food Specialities (BECTORSFOOD)

CMP: ₹375
Target: ₹455

ANAND RATHI
INVESTMENT SERVICES


Rationale:

- Mrs.Bectors Food Specialities Limited (MBFSL) is one of the leading companies in the premium and mid-premium biscuits and premium bakery segment in North India. It manufactures and markets range of biscuits, cookies, creams, breads, buns, pizza bases etc, under its two major flagship brand 'Mrs.Bector's Cremica' & 'English Oven' with a PAN India distribution presence across 26 states & 3 UT and 200k+ direct reach including 550+ Retail outlets.
- MBFL is a strong player in the biscuits and bakery segment. As of FY20 In the biscuits segment the company had ~4.5% market share in the premium and mid-premium biscuits market in North India. Its share in the total exports of biscuits from India was ~12% in CY19. In the bakery segment, the company's share is 5% of the branded breads segment in India. The company manufactures and supplies to leading QSRs, Cloud Kitchens and Multiplexes and has an 11% market share in semi-processed and dough-based offerings.
- MBFSL has emerged as a leading player in the biscuits and bakery segment among stiff competition from not only bigger players like Britannia, ITC & Parle but also the unorganized market which holds 30% share in the branded biscuits market with over 66% market share of above mentioned big players. As of FY20, MBFL's biscuit brand 'Cremica' had a market of 1% on a PAN India level suggesting huge opportunity of growth ahead with aggressive capacity expansion plans and rapid increase in its direct reach.
- The company is planning to further increase its presence in North India and similarly planning to double its direct reach from 200k to 450k in coming few years with existing presence of 550k+ retail outlets in General Trade across India. Along with increasing its distribution reach it has also planned capex worth Rs.1,635 Mn including greenfield and brownfield expansion of its Biscuits and Bakery categories till FY24E.
- With Branded biscuits, Breads & Buns & Chain QSR Market expected to grow at a CAGR of 12%/11%/29% we expect huge runway of growth ahead for Mrs.Bectors Food owing to (a) rapidly increasing distribution and continuous innovation in domestic biscuits, (b) capturing a greater biscuit export client share, (c) increasing market reach in branded breads, and (d) enhancing product portfolio and deepening relationships with leading QSR players. We recommend a **BUY** rating on MBFSL with a Target Price of of **₹455per share**.

52 Week Low / High	1051.00 / 1848.25
Avg. Daily Volume (3M)	195
No. of Shares O/S (Mn.) / Mkt. Cap (₹Mn.)	58.82 / 22,180
Shareholding (Promoters/Institutional/Others)	51.1% / 1.3% / 47.6%

(In ₹ mn)	FY-21	FY-22	FY-23E	FY-24E
Total Income	8,807	9,882	11,631	13,480
EBITDA	1,414	1,228	1,428	1,824
EBITDA Margin	16.06%	12.43%	12.28%	13.53%
PAT	722	571	642	861
PAT Margin	8.20%	5.78%	5.52%	6.39%
EPS (₹)	12.3	9.7	10.7	14.5
Debt/Equity	0.1	0.1	0.1	0.1
P/B	5.1	4.7	4.2	3.9
RoE	16.74%	12.18%	14.24%	17.77%
P/E	30.7	38.8	37.4	31.4

Source: Company, Anand Rathi Research, Bloomberg. Note: Prices are as on 14-Oct-22



Linde India Limited (LINDEINDIA)

CMP: ₹3,150
Target: ₹3,800

ANAND RATHI
INVESTMENT SERVICES

Rationale:

- Linde India Limited is a leading industrial gases and engineering company in India. The company is engaged in manufacture of industrial and medical gases and construction of cryogenic and non-cryogenic air separation plant. Its business has two broad segments: Gases and Related Products and Project Engineering.
- The Gases and Related Products segment comprises of pipeline gas supplies (Onsite) to large industrial customers, mainly the primary steel, glass and chemical industries, supply of liquefied gases through Cryogenic tankers (Bulk) to cater to mid-size demands across a wide range of industrial sectors and compressed gas supply in cylinders (Packaged Gas) for meeting smaller demand for gases mainly across fabrication, manufacturing and construction industry. The Project Engineering Division comprises the business of design, engineering, supply, installation, testing and commissioning of Air Separation plants and related projects on turnkey basis.
- The Company's product find its application in manufacturing industries like Steel, Automotive, Cement, FMCG, Pharma etc. The 'Make in India' initiative of the Govt. and the Budget proposals are aimed at boosting the contribution made by the manufacturing sector. Such Initiative by the Govt. will help increase the demand for industrial gas product portfolio of the company.
- Linde India has successfully acquired the business of HPS Gases Ltd. at an aggregate cash consideration of ₹275 million to increase its gases business in merchant and mini bulk segment in the western markets. It has also been making new investments towards construction of new merchant air separation units (ASU) (250 tonnes per day) at Dahej at a capex of Rs.1,386 million and another ASU (264 tonnes per day) near Ludhiana at a capex of Rs.1,521 million. The new ASU is expected to be on stream by Q3FY23. It is also constructing an onsite large ASU (900 tonnes per day) at ESL Ltd. steel works at Bokaro.
- Linde South Asia Services Private Ltd, a Joint Venture company between Linde India Ltd. and Praxair India Private Ltd has an O&M Agreement with both the JV partners. Such partnership will provide Synergy benefits to the Company.
- We believe that the company will benefit from government thrust towards manufacturing, synergy benefit from JV and upcoming capacities. We recommend a **BUY** on the stock with a target price of **₹3,800 per share.**

52 Week Low / High	2259/4190
Avg. Daily Volume (3M)	65
No. of Shares O/S (Mn.) / Mkt. Cap (₹Mn.)	85.28/2,68,645
Shareholding (Promoters/Institutional/Others)	75%/10.6%/14.4%

(In ₹ mn)	FY-20	FY-21	FY-22E	FY-23E
Total Income	14,711	21,120	24,650	28,250
EBITDA	3,748	5,457	6,767	8,560
EBITDA Margin	25.5%	25.8%	24.0%	26.5%
PAT	1,511	5,072	3,839	5,098
PAT Margin	10.3%	24.0%	15.6%	18.0%
EPS (₹)	17.7	59.5	45.0	59.8
Debt/Equity	0	0	0	0
P/B	12.0	9.9	9.2	8.3
RoE	6.8%	18.7%	13.3%	15.8%
P/E	177.8	53.0	70.0	52.7

Source: Company, Anand Rathi Research, Bloomberg. Note: Prices are as on 14-Oct-22

Price Performance (Oct'21=100)



Disclaimer:

Analyst Certification

❑ The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter “SEBI”) and the analysts’ compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Ratings Methodology

❑ Analysts’ ratings and the corresponding expected returns take into account our definitions of Large Caps (>₹300 Billion) and Mid/Small Caps (<₹300 Billion) or SEBI definition vide its circular SEBI/HO/IMD/DF3/CIR/P/2017/114 dated 6th October 2017, whichever is higher and as described in the Ratings Table below:

Ratings Guide (12 months)	Buy	Hold	Sell
Large Caps (>₹300Bn.)	15%	5%-10%	Below 5%
Mid/Small Caps (<₹300 Bn.)	20%	10%-15%	Below 10%

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity, SEBI Regn No. INH000000834, Date of Regn. 29/06/2015) is a subsidiary of the Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd, National Stock Exchange of India Ltd. (NSEIL), Multi Stock Exchange of India Ltd (MCX-SX), and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. ARSSBL is engaged into the business of Stock Broking, Depository Participant, Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues.

General Disclaimer: - This Research Report (hereinafter called “Report”) is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers.No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. ARSSBL does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding taxation aspects of any potential investment.

Continued...

Contd...

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i. e. www.rathi.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Copyright: - This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

Contd...

Contd.
Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates.

Sr. No.	Statement	Answers to the Best of the knowledge and belief of the ARSSBL/ its Associates/ Research Analyst who is preparing this report
1	ARSSBL/its Associates/ Research Analyst/ his Relative have any financial interest in the subject company? Nature of Interest (if applicable), is given against the company's name?.	NO
2	ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?.	NO
3	ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report or at the time of public appearance?.	NO
4	ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months.	NO
5	ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months.	NO
6	ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.	NO
7	ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months.	NO
8	ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report.	NO
9	ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	NO
10	ARSSBL/its Associates/ Research Analyst/ his Relative has been engaged in market making activity for the subject company.	NO

Thank You